References
1. Jones T, Mühlemann B, Veith T, et al. An analysis of SARS-CoV-2 viral
load by patient age. medRxiV: Preprint Server for Health Sciences2020: doi:10.1101/2020.06.08.20125484
2. Ludvigsson JF. Children are unlikely to be the main drivers of the
COVID-19 pandemic - A systematic review. Acta Paediatr 2020;109 : 1525-30.
3. Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2
in the Icelandic Population. N Engl J Med 2020 ; 382 :
2302-15.
4. Munro APS, Faust SN. Children are not COVID-19 super spreaders: time
to go back to school. Arch Dis Child 2020; 105 : 618-9.
5. Davies P, Evans C, Kanthimathinathan HK, et al. Intensive care
admissions of children with paediatric inflammatory multisystem syndrome
temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre
observational study. Lancet Child Adolesc Health 2020;4 : 669-77.
6. Kaushik S, Aydin SI, Derespina KR, et al. Multisystem Inflammatory
Syndrome in Children Associated with Severe Acute Respiratory Syndrome
Coronavirus 2 Infection (MIS-C): A Multi-institutional Study from New
York City. J Pediatr 2020; 224 : 24-9.
7. Whittaker E, Bamford A, Kenny J, et al. PIMS-TS Study Group and
EUCLIDS and PERFORM Consortia. Clinical Characteristics of 58 Children
with a Pediatric Inflammatory Multisystem Syndrome Temporally Associated
With SARS-CoV-2. JAMA . 2020; 21;324(3):259-269.
8. Ahmed M, Advani S, Moreira A, et al. Multisystem inflammatory
syndrome in children: A systematic review. EClinicalMedicine2020; 26 : 100527.
9. Chang LY, Lu CY, Shao PL, et al. Viral infections associated with
Kawasaki disease. J Formos Med Assoc 2014; 113 : 148-54.
10. Rothan HA, Byrareddy SN. The potential threat of multisystem
inflammatory syndrome in children during the COVID-19 pandemic.Pediatr Allergy Immunol 2020: doi:10.1111/pai.13361.
11. Brandstetter S, Roth S, Harner S, et al. Symptoms and immunoglobulin
development in hospital staff exposed to a SARS-CoV-2 outbreak.Pediatr Allergy Immunol 2020: doi:10.1111/pai.13278.
12. Peterhoff D, Gluck V, Vogel M, et al. A highly specific and
sensitive serological assay detects SARS-CoV-2 antibody levels in
COVID-19 patients that correlate with neutralization. Infection2020: doi:10.1007/s15010-020-01503-7.
13. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell
Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven
Protease Inhibitor. Cell 2020; 181 : 271-80 e8.
14. Schmidt F, Weisblum Y, Muecksch F, et al. Measuring SARS-CoV-2
neutralizing antibody activity using pseudotyped and chimeric viruses.J Exp Med 2020; 217 : doi:10.1084/jem.20201181.
15. Hippich M, Holthaus L, Assfalg R, et al. Public health antibody
screening indicates a six-fold higher SARS-CoV-2 exposure rate than
reported cases in children. Med (N Y) 2020: Oct 29. doi:
10.1016/j.medj.
16. Fill Malfertheiner S, Brandstetter S, Roth S, et al. Immune response
to SARS-CoV-2 in health care workers following a COVID-19 outbreak: A
prospective longitudinal study. J Clin Virol 2020; 130 :
104575.
17. Kuri-Cervantes L, Pampena MB, Meng W, et al. Comprehensive mapping
of immune perturbations associated with severe COVID-19. Sci
Immunol 2020; 5 : doi:10.1126/sciimmunol.abd7114.
18. Almqvist J, Granberg T, Tzortzakakis A, et al. Neurological
manifestations of coronavirus infections - a systematic review.Ann Clin Transl Neurol 2020; 7 : 2057-71.
19. Gruber CN, Patel RS, Trachtman R, et al. Mapping Systemic
Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome
in Children (MIS-C). Cell 2020; 183 : 982-95 e14.
20. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment,
and Long-Term Management of Kawasaki Disease: A Scientific Statement for
Health Professionals From the American Heart Association.Circulation 2017; 135 : e927-e99.